These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 17869669

  • 1. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):560-71. PubMed ID: 17869669
    [Abstract] [Full Text] [Related]

  • 2. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
    Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR.
    Cancer Res; 2009 May 01; 69(9):3884-91. PubMed ID: 19366798
    [Abstract] [Full Text] [Related]

  • 3. A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
    Patel K, Choy SS, Hicks KO, Melink TJ, Holford NH, Wilson WR.
    Cancer Chemother Pharmacol; 2011 May 01; 67(5):1145-55. PubMed ID: 20683596
    [Abstract] [Full Text] [Related]

  • 4. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV.
    Biochem Pharmacol; 2007 Sep 15; 74(6):810-20. PubMed ID: 17645874
    [Abstract] [Full Text] [Related]

  • 5. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures.
    Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR.
    Cancer Res; 2003 Sep 15; 63(18):5970-7. PubMed ID: 14522924
    [Abstract] [Full Text] [Related]

  • 6. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV.
    Cancer Res; 2010 Feb 15; 70(4):1573-84. PubMed ID: 20145130
    [Abstract] [Full Text] [Related]

  • 7. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.
    Radiat Res; 2007 Jun 15; 167(6):625-36. PubMed ID: 17523848
    [Abstract] [Full Text] [Related]

  • 8. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
    Gu Y, Guise CP, Patel K, Abbattista MR, Li J, Sun X, Atwell GJ, Boyd M, Patterson AV, Wilson WR.
    Cancer Chemother Pharmacol; 2011 Mar 15; 67(3):543-55. PubMed ID: 20473609
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
    Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR.
    Clin Cancer Res; 2007 Jul 01; 13(13):3922-32. PubMed ID: 17606726
    [Abstract] [Full Text] [Related]

  • 10. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.
    Hay MP, Pchalek K, Pruijn FB, Hicks KO, Siim BG, Anderson RF, Shinde SS, Phillips V, Denny WA, Wilson WR.
    J Med Chem; 2007 Dec 27; 50(26):6654-64. PubMed ID: 18052317
    [Abstract] [Full Text] [Related]

  • 11. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.
    Pruijn FB, Sturman JR, Liyanage HD, Hicks KO, Hay MP, Wilson WR.
    J Med Chem; 2005 Feb 24; 48(4):1079-87. PubMed ID: 15715475
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.
    Clin Cancer Res; 2010 Oct 15; 16(20):4946-57. PubMed ID: 20732963
    [Abstract] [Full Text] [Related]

  • 13. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans.
    Gu Y, Atwell GJ, Wilson WR.
    Drug Metab Dispos; 2010 Mar 15; 38(3):498-508. PubMed ID: 20019245
    [Abstract] [Full Text] [Related]

  • 14. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.
    Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, Denny WA, Dewhirst MW, Wilson WR.
    J Natl Cancer Inst; 2006 Aug 16; 98(16):1118-28. PubMed ID: 16912264
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
    Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, Denny WA.
    J Med Chem; 2007 Dec 13; 50(25):6392-404. PubMed ID: 18001018
    [Abstract] [Full Text] [Related]

  • 16. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
    Foehrenbacher A, Patel K, Abbattista MR, Guise CP, Secomb TW, Wilson WR, Hicks KO.
    Front Oncol; 2013 Dec 13; 3():263. PubMed ID: 24109591
    [Abstract] [Full Text] [Related]

  • 17. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
    Kyle AH, Minchinton AI.
    Cancer Chemother Pharmacol; 1999 Dec 13; 43(3):213-20. PubMed ID: 9923551
    [Abstract] [Full Text] [Related]

  • 18. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
    Gu Y, Tingle MD, Wilson WR.
    J Pharmacol Exp Ther; 2011 Jun 13; 337(3):692-702. PubMed ID: 21427202
    [Abstract] [Full Text] [Related]

  • 19. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, Wilson WR.
    Biochem Pharmacol; 2012 Mar 01; 83(5):574-85. PubMed ID: 22182429
    [Abstract] [Full Text] [Related]

  • 20. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
    Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su J, Li D, Wilson WR, Dachs GU, Patterson AV.
    Mol Pharmacol; 2012 Jan 01; 81(1):31-40. PubMed ID: 21984255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.